Transplant-Related Accelerated Progression of Hepatitis C

NCT00368225 | Completed

• 2 other identifiers: 06019306-CC-0193
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 3

Brief Summary

This study will explore why severe scarring of the liver (cirrhosis) develops so rapidly in hepatitis C-infected patients who have had a liver transplant and possibly in kidney transplant patients as well. The hepatitis C virus (HCV) can cause cirrhosis in about 20 percent of infected persons. Generally, it takes 20 years or more for cirrhosis to develop. After liver transplantation, however, patients may develop cirrhosis in as little as 5 years. Cirrhosis does not develop as rapidly in kidney transplant patients, but it may develop faster than in people who do not undergo transplantation. The study will look at the possible role of immune-suppressing medications given to liver and kidney transplant patients in increasing the severity of hepatitis C infection and in speeding the cirrhotic process. Patients 18 years of age and older with chronic HCV infection who require a liver transplant for end-stage liver disease or a kidney transplant for kidney failure may be eligible for this study. Liver transplant patients are recruited from the Inova Fairfax Liver Transplant Center in Fairfax, Virginia, and from the Georgetown University Medical Center Liver Transplant Institute in Washington, D.C. Kidney transplant patients are recruited from the Transplantation Branch of the National Institute of Diabetes and Digestive and Kidney Diseases. Participants undergo the following procedures:

• Regular care: As part of their regular transplant-related treatment, patients have a medical history, physical examinations and blood draws before their transplant and on regularly scheduled visits after the transplant.
• Blood draws for research: Special blood tests are done to measure the immune response to HCV. They measure the amount of HCV in the blood, the number of HCV strains present and how they change over time and the HCV antibodies in the blood.
• Liver biopsies: This procedure is done at 3 months, 1 year, 3 years and 5 years after the transplant to determine the extent of scarring of the liver and to study the immune responses within the liver, the proportion of liver cells infected with HCV and the presence of scar-producing cells. The biopsy is done during a 1- to 2-day inpatient hospital stay. The patients are given a sedative medication through a vein before the procedure. The skin over the biopsy site is numbed and the biopsy needle is passed rapidly into and out of the liver to collect a small sample of liver tissue for study.
• Apheresis: This procedure is done to collect a large number of white blood cells needed to test the immune response to the HCV. On the day before each liver biopsy, blood is drawn through a needle from a vein in one arm and run through a machine that separates and collects the white cells. The red cells and plasma are returned to the patient's body through the same needle or a second needle in the other arm.

Conditions

Hepatitis C; Cirrhosis

Keywords

Viral Hepatitis; Hepatitis C; HCV; Liver Transplant; Renal Transplant; Kidney Transplant

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• To fulfill criteria for study entry, the patient must:
• be 18 years of age or older.
• have detectable HCV RNA
• require orthotopic liver transplantation for chronic hepatitis C induced cirrhosis or require renal transplantation for end-stage kidney disease
• have a MELD score greater than 18 (for liver transplant patients) or have an otherwise high probability of receiving a liver or kidney transplant within six months of enrollment based on assessment by the clinical transplant team at each hospital.
• be able/willing to travel to the collaborating center for blood sampling prior to liver or kidney transplantation, and at 2, 3, 4, 5, 6, 8, 12, 16, 24 weeks after transplantation and then bi-annually until the end of the study at 5 years
• be willing to have study-related liver biopsies at 3 months, and then 1, 3 and 5 years after transplantation
• provide informed consent.

You may not qualify if:

• To fulfill criteria for study entry, the patient must NOT:
• be HIV or Hepatitis B virus (HBsAg) positive
• receive a liver graft from an anti-HCV antibody positive or HBV core positive donor
• have other forms of liver disease including primary biliary cirrhosis, autoimmune hepatitis, hemochromatosis and Wilson's Disease
• have hepatocellular carcinoma if any single lesion is 5 cm. or more or if there are 3 or more lesions exceeding 3 cm.
• be on immunomodulatory medications such as corticosteroids within four weeks of collection of blood for pre-transplant baseline laboratory testing
• have been diagnosed with any hereditary or acquired immunodeficiency state prior to liver or kidney transplantation

Sponsors & Collaborators

• National Institutes of Health Clinical Center (CC): lead

Study Sites (3)

Georgetown University

Washington D.C., District of Columbia, 20007-2197, United States

Location

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Inova Fairfax Hospital

Falls Church, Virginia, 22042, United States

Location

Related Publications (3)

• Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999 Aug 19;341(8):556-62. doi: 10.1056/NEJM199908193410802.

  PMID: 10451460 BACKGROUND

• Davis GL. Chronic hepatitis C and liver transplantation. Rev Gastroenterol Disord. 2004 Winter;4(1):7-17.

  PMID: 15029106 BACKGROUND

• Sheiner PA, Schluger LK, Emre S, Thung SN, Lau JY, Guy SR, Schwartz ME, Miller CM. Retransplantation for recurrent hepatitis C. Liver Transpl Surg. 1997 Mar;3(2):130-6. doi: 10.1002/lt.500030205.

  PMID: 9346726 BACKGROUND

MeSH Terms

Conditions

Hepatitis C; Fibrosis

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Hepatitis, Viral, Human; Virus Diseases; Flaviviridae Infections; RNA Virus Infections; Hepatitis; Liver Diseases; Digestive System Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: NIH

Study Record Dates

• First Submitted: August 23, 2006
• First Posted: August 24, 2006
• Study Start: June 22, 2006
• Study Completion: January 22, 2009
• Last Updated: July 2, 2017

Record last verified: 2009-01-22

Locations

US (3)